Evolving Therapeutic Options for Chronic Graft-versus-Host Disease

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Chronic graft-versus-host disease (cGVHD) remains a major cause of morbidity and mortality in allogeneic transplant recipients.
• It is influenced by donor, patient, and hematopoietic cell transplant (HCT) factors, presenting significant post-transplant complications.
• Understanding cGVHD pathophysiology is crucial for developing improved clinical interventions.

Purpose of the Study:

• To review recent advances in understanding cGVHD pathophysiology.
• To highlight new approaches for the prevention and treatment of cGVHD.
• To discuss the impact of novel agents and expanded therapeutic strategies.

Main Methods:

• Review of current literature on cGVHD.
• Analysis of recent clinical trials and therapeutic advancements.
• Discussion of emerging biological insights into cGVHD.

Main Results:

• Posttransplantation cyclophosphamide shows promise beyond haploidentical HCTs, transforming outcomes.
• Novel agents are being investigated in combination with corticosteroids for upfront therapy.
• Ibrutinib is the first FDA-approved agent for cGVHD, marking a significant therapeutic advance.
• Several treatment options for steroid-refractory cGVHD are under investigation.

Conclusions:

• Advances in understanding cGVHD pathophysiology are driving innovation in prevention and treatment.
• Expanded use of posttransplantation cyclophosphamide and novel therapeutic agents offer improved outcomes.
• Future research focuses on mitigating steroid exposure and managing refractory disease.